← Back to Clinical Trials
Recruiting NCT06203652

NCT06203652 The Pathogenesis and Prognostic Factors of Lymphoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06203652
Status Recruiting
Phase
Sponsor Shanghai Zhongshan Hospital
Condition Lymphoma
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2023-06-05
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Real-world regimen

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2023-06-05 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to describe the clinical and genetic characteristics of Chinese lymphoma patients, and to explore the relationship between those characteristics and phatogenesis.

Eligibility Criteria

Inclusion Criteria: * Patients with pathological diagnosis of lymphoma (including Hodgkin lymphoma and non-Hodgkin lyphoma, eg. THRLBCL, DLBCL, MZL, CLL/SLL...) from 2007 to 2027. * Patients with complete diagnostic, treatment and follow-up records. * Fully comprehension and signature of the informed consent form (ICF) for participation. Exclusion Criteria: * Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period. * Severe mental illness. * Patients deemed unsuitable for inclusion by the investigator.

Contact & Investigator

Central Contact

Peng Liu, Ph.D

✉ liu.peng@zs-hospital.sh.cn

📞 +862164041990

Frequently Asked Questions

Who can join the NCT06203652 clinical trial?

This trial is open to participants of all sexes, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06203652 currently recruiting?

Yes, NCT06203652 is actively recruiting participants. Contact the research team at liu.peng@zs-hospital.sh.cn for enrollment information.

Where is the NCT06203652 trial being conducted?

This trial is being conducted at Shanghai, China.

Who is sponsoring the NCT06203652 clinical trial?

NCT06203652 is sponsored by Shanghai Zhongshan Hospital. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology